24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
L-GANASELIEVA 10000IU is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | L-GANASELIEVA 10000IU |
|---|---|
| Composition | L-Asparaginase Injection 10000IU |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
L-GANASELIEVA 10000IU (L-Asparaginase Injection 10000IU) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
L-GANASELIEVA 10000 IU (L-Asparaginase Injection 10000 IU) is a prescription anticancer medicine used in the treatment of Acute Lymphoblastic Leukemia (ALL) and certain other hematological malignancies. It contains L-Asparaginase 10000 IU, an enzyme-based chemotherapy agent that helps destroy leukemia cells by reducing the levels of asparagine, an essential amino acid required for the survival and growth of specific cancer cells.
Acute Lymphoblastic Leukemia is a cancer of the blood and bone marrow characterized by the rapid production of abnormal white blood cells. Unlike healthy cells, leukemia cells often lack the ability to produce sufficient amounts of asparagine on their own and depend on circulating asparagine for survival. L-GANASELIEVA 10000 IU works by breaking down asparagine in the bloodstream, depriving leukemia cells of a critical nutrient and leading to their destruction.
L-Asparaginase has been a cornerstone of leukemia treatment for many years and is commonly included in modern chemotherapy protocols for both pediatric and adult patients. Its unique mechanism of action makes it an important addition to combination chemotherapy regimens designed to improve treatment success and long-term outcomes.
L-GANASELIEVA 10000 IU is commonly prescribed for:
The medicine is usually administered under strict medical supervision in hospitals, cancer centers, and specialized hematology facilities. Treatment plans are individualized based on the patient’s age, body size, disease condition, and overall treatment protocol.
Manufactured under stringent pharmaceutical quality standards, L-GANASELIEVA 10000 IU is designed to ensure consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology care.
Patients undergoing treatment with L-Asparaginase often require regular laboratory monitoring, including blood counts, liver function tests, pancreatic assessments, blood clotting evaluations, and routine clinical examinations to ensure safe and effective therapy.
Due to its proven effectiveness in leukemia treatment, L-GANASELIEVA 10000 IU remains an important medicine in modern pediatric and adult oncology care worldwide.
L-GANASELIEVA 10000 IU (L-Asparaginase Injection 10000 IU) is primarily used for the treatment and management of leukemia and related blood cancers.
The medicine is widely used in standard treatment protocols for acute lymphoblastic leukemia.
L-Asparaginase plays an important role in childhood leukemia management.
The medicine may be prescribed as part of comprehensive treatment plans for adults diagnosed with ALL.
L-GANASELIEVA is often administered alongside other anticancer medicines to enhance treatment effectiveness.
The medicine may be included in selected treatment protocols for blood-related cancers.
It supports comprehensive leukemia treatment and long-term disease management strategies.
L-Asparaginase belongs to a class of medicines known as enzyme-based antineoplastic agents.
L-GANASELIEVA works by:
This targeted mechanism helps eliminate leukemia cells while supporting overall cancer treatment goals.
Like all prescription medicines, L-GANASELIEVA 10000 IU may cause side effects in some patients. The severity and frequency of side effects vary depending on individual response and treatment conditions.
Patients may experience mild to moderate nausea during therapy.
Episodes of vomiting may occur in some individuals.
Weakness and reduced energy levels are commonly reported.
Mild fever may develop during treatment.
Some patients may experience decreased appetite.
Pain, redness, swelling, or irritation at the injection site may occur.
Mild to moderate abdominal discomfort may develop.
Temporary changes in liver function test results may occur.
The medicine may affect normal blood clotting mechanisms and require monitoring.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of L-GANASELIEVA 10000 IU (L-Asparaginase Injection 10000 IU) should always be determined by a qualified oncologist or hematologist.
Treatment schedules vary depending on the diagnosed condition.
Pediatric and adult dosing protocols may differ.
Dosage is often calculated according to body size and treatment requirements.
The medicine is commonly used within combination chemotherapy regimens.
Doctors may adjust treatment according to effectiveness and patient tolerance.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of Acute Lymphoblastic Leukemia (ALL) and selected blood-related cancers.
L-Asparaginase is an enzyme-based anticancer medicine that reduces asparagine levels required by leukemia cells to survive and grow.
Yes, it is an important anticancer medicine commonly used in combination chemotherapy treatment protocols.
Yes, it is widely used in pediatric leukemia treatment under specialist supervision.
Yes, liver function monitoring is often required during treatment because temporary liver-related changes may occur.
Blood tests help monitor treatment response, liver health, clotting status, and overall patient safety.
No, treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, hematology, and leukemia treatment.